World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
47833
World Ranking
5317
National Ranking
2870

Overview

Jan A. Burger is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on Medicine, with a substantial contribution to related subfields such as Genetics, Hematology, Pathology and Forensic Medicine, Immunology, and Molecular Biology.

Their work extensively covers topics including Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Immunodeficiency and Autoimmune Disorders, Acute Lymphoblastic Leukemia Research, and Advanced Breast Cancer Therapies.

Burger has published in several prominent scientific venues. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • Leukemia
  • Leukemia & lymphoma/Leukemia and lymphoma

Some of Burger's recent papers are:

  • Treatment of Chronic Lymphocytic Leukemia, 2020, New England Journal of Medicine
  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial, 2020, The Lancet Haematology
  • Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia, 2022, Blood Advances
  • Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study, 2020, Clinical Cancer Research
  • Molecular map of chronic lymphocytic leukemia and its impact on outcome, 2022, Nature Genetics

Burger frequently collaborates with researchers such as:

  • Alessandra Ferrajoli
  • Nitin Jain
  • William G. Wierda
  • Hagop M. Kantarjian
  • Tapan M. Kadia

The body of Burger's research demonstrates a focus on the genetic and molecular basis of hematologic malignancies as well as clinical approaches to treatment. Their work intersects fundamental biology and clinical investigations, contributing knowledge to the application of novel therapies in leukemia and lymphoma management.

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

    Jan A. Burger;Thomas J. Kipps;Thomas J. Kipps

  • Mesenchymal precursor cells in the blood of normal individuals

    Nathan J Zvaifler;Lilla Marinova-Mutafchieva;Gill Adams;Christopher J Edwards

  • Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

    Jan A. Burger;Nobuhiro Tsukada;Meike Burger;Nathan J. Zvaifler

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

    Sabine Ponader;Shih Shih Chen;Joseph J. Buggy;Kumudha Balakrishnan

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • The microenvironment in mature B-cell malignancies: a target for new treatment strategies

    Jan A. Burger;Paolo Ghia;Andreas Rosenwald;Federico Caligaris-Cappio

  • The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

    Julia Hoellenriegel;Sarah A. Meadows;Mariela Sivina;William G. Wierda

  • Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

    Jan A. Burger;Meike Burger;Meike Burger;Thomas J. Kipps

  • CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

    J A Burger;A Peled

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells.

    Lukas Bossaller;Jan Andreas Burger;Ruth Draeger;Bodo Grimbacher

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

    Jan A Burger;Michael J Keating;William G Wierda;Elena Hartmann

  • Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Jan A. Burger;Paul M. Barr;Tadeusz Robak;Carolyn Owen

  • B cell receptor signaling in chronic lymphocytic leukemia.

    Jan A. Burger;Nicholas Chiorazzi

  • Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Talha Munir;Jennifer R. Brown;Susan O'Brien;Jacqueline C. Barrientos

Frequent Co-Authors

William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking alternatives to traditional medical school, a wide range of online degrees and career pathways are available. Many of these programs offer flexible schedules and accelerated formats, making them ideal for busy professionals or career changers.

For example, individuals interested in preventive health and wellness may consider online nutrition degree programs, which delve into the science of diet and its impact on health outcomes. Those aiming for healthcare leadership roles might pursue one of the cahme accredited online mha programs list to gain critical management expertise.

Nurses looking to advance their careers without spending extra time in clinical settings can explore online rn to bsn programs no clinicals, while experienced nurses wanting to reach the top of clinical practice can find expedited options with the fastest dnp program choices.

Each of these online pathways opens the door to meaningful healthcare careers, offering accessible and respected routes to advancement in the medical field.

Best Scientists Citing Jan A. Burger

Trending Scientists

Recently Published Articles